Pharvaris (NASDAQ:PHVS) Price Target Cut to $74.00 by Analysts at Citizens Jmp

Pharvaris (NASDAQ:PHVS) had its price target cut by Citizens Jmp from $75.00 to $74.00 in a note issued to investors on Wednesday,Benzinga reports. The firm currently has a “market outperform” rating on the stock. Citizens Jmp’s price target points to a potential upside of 130.64% from the stock’s current price.

A number of other equities research analysts have also recently commented on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Pharvaris in a research note on Tuesday, April 21st. HC Wainwright reissued a “buy” rating and set a $60.00 price target on shares of Pharvaris in a report on Tuesday, March 3rd. Wall Street Zen lowered shares of Pharvaris from a “sell” rating to a “strong sell” rating in a research report on Monday, April 13th. Wolfe Research started coverage on shares of Pharvaris in a report on Thursday, April 9th. They issued an “outperform” rating and a $42.00 target price for the company. Finally, Royal Bank Of Canada lowered their price target on Pharvaris from $52.00 to $51.00 and set an “outperform” rating on the stock in a report on Monday, April 6th. Eleven analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $47.17.

Pharvaris Trading Up 2.7%

Shares of NASDAQ:PHVS traded up $0.84 during trading on Wednesday, reaching $32.09. 16,062 shares of the company traded hands, compared to its average volume of 216,439. The business’s fifty day moving average is $27.89 and its 200-day moving average is $26.41. Pharvaris has a 52-week low of $14.59 and a 52-week high of $32.04. The firm has a market capitalization of $2.10 billion, a price-to-earnings ratio of -9.50 and a beta of -2.34.

Pharvaris (NASDAQ:PHVS) last posted its earnings results on Friday, April 3rd. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.15). On average, sell-side analysts predict that Pharvaris will post -3.14 earnings per share for the current fiscal year.

Insider Transactions at Pharvaris

In other news, insider Peng Lu sold 15,000 shares of the company’s stock in a transaction dated Thursday, April 30th. The shares were sold at an average price of $30.24, for a total value of $453,600.00. Following the transaction, the insider directly owned 66,083 shares in the company, valued at approximately $1,998,349.92. This represents a 18.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Anne Lesage sold 21,700 shares of the firm’s stock in a transaction dated Thursday, April 30th. The stock was sold at an average price of $30.26, for a total transaction of $656,642.00. Following the completion of the transaction, the insider directly owned 56,450 shares in the company, valued at $1,708,177. This represents a 27.77% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 150,659 shares of company stock worth $4,489,587.

Institutional Investors Weigh In On Pharvaris

Several large investors have recently added to or reduced their stakes in the stock. California State Teachers Retirement System raised its position in Pharvaris by 2.2% during the 4th quarter. California State Teachers Retirement System now owns 23,982 shares of the company’s stock valued at $666,000 after purchasing an additional 520 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Pharvaris by 30.6% in the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after acquiring an additional 783 shares during the period. GF Fund Management CO. LTD. bought a new position in Pharvaris during the 4th quarter worth about $35,000. Public Employees Retirement System of Ohio increased its position in Pharvaris by 20.7% during the 4th quarter. Public Employees Retirement System of Ohio now owns 7,569 shares of the company’s stock valued at $210,000 after purchasing an additional 1,300 shares during the period. Finally, Legal & General Group Plc increased its position in Pharvaris by 17.2% during the 2nd quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock valued at $203,000 after purchasing an additional 1,695 shares during the period.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.